Topic: Cofactor Genomics - Sponsored
Despite major breakthroughs in cancer treatments, less than 20% of patients respond to even the most innovative immunotherapies. The reason is the industry’s reliance on imperfect, single-analyte biomarkers, using antiquated methods to match patients to therapies. Cofactor’s team of 20-year veterans in genomics, knowing the inherent limitations of DNA and proteins, instead are using the power of RNA to build the technologies, data assets, and regulatory frameworks to enable more predictive multidimensional biomarkers. Driven by clinical and market data, we’ve prioritized a list of key cancer subtypes that address the highest unmet clinical need.